Marek Hartleb

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

David Jones, Pol Boudes, Mark G. Swain et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 186 citations

Medicine, Pharmacology, Pharmacotherapy +12

Serum chemerin and vaspin in non-alcoholic fatty liver disease

Michał Kukla, K Zwirska-Korczala, Marek Hartleb et al. · Scandinavian Journal of Gastroenterology · 2010 · 132 citations

Medicine, Biochemistry, Endocrinology +17

Vascular hyporesponsiveness to endothelin 1 in rats with cirrhosis

Marek Hartleb, Richard Moreau, Stéphane Cailmail et al. · Gastroenterology · 1994 · 84 citations · Full text

Medicine, Pharmacology, Physiology +10

Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD)

Joanna Raszeja‐Wyszomirska, Barbara Szymanik, Małgorzata Ławniczak et al. · BMC Gastroenterology · 2010 · 63 citations · Full text

Medicine, Internal Medicine, Pathology +17